WTW inhabitants well being chief Jeff Levin-Scherz on what brokers should do earlier than 2027 renewals
Healthcare prices for US employers are on monitor to rise 11.1 % in 2027 with out plan adjustments – the steepest projected enhance in roughly twenty years – and even employers that act aggressively can count on a 9.5 % soar, in accordance with WTW’s 2026 Finest Practices in Healthcare Survey of 471 US employers.
The findings land on the worst doable second: 62 % of employers had been already over funds in 2025, exceeding their targets by a median of 5.6 share factors, and 78 % say they’re experiencing extra monetary stress from healthcare prices than at any level prior to now decade.
In an interview with Insurance coverage Enterprise Advantages US, Jeff Levin-Scherz, inhabitants well being chief at WTW, says the forces pushing prices upward are structural and unlikely to ease within the close to time period.
“Medical prices have elevated resulting from a mix of structural points,” he stated. “The primary is innovation – we’re shopping for big advances in oncology and remedy of inflammatory ailments, and these value extra. The second is normal inflation. Medical suppliers are paying extra for labor and provides, identical to different companies. The third is supplier consolidation. There are basically no markets with strong hospital competitors, and within the industrial market the well being plans are fragmented and none has the leverage to insist on decrease costs.”
The survey reinforces that view: 80 % of employers count on elevated healthcare prices for a minimum of the following three years, and 65 % count on the stress to persist for 5 years or extra. Examine that to wage progress hovering round 3.5 %, and the squeeze going through plan sponsors turns into clear.
A price-shift that carries workforce threat
The monetary stress is forcing a reckoning for employer plan sponsors. By 2028, 85 % of employers are planning or contemplating elevating worker premium contributions, up from 44 % immediately, in accordance with WTW.
Out-of-pocket value will increase are following the identical trajectory, rising from 30 % of employers in 2023 to a projected 71 % by 2028. Levin-Scherz warns that the cumulative impact of those shifts carries a threat many plan sponsors are underestimating.
“Employers are in a tough place as a result of adjustments in plan design yield early and sure financial savings, and lots of different interventions take a very long time to mature and have vital execution threat,” he stated.
Levin-Scherz pointed to a Commonwealth Fund examine – The State of Well being Insurance coverage Protection in 2026, revealed October 22, 2026 – that paperwork excessive charges of underinsurance, together with amongst employees with employer-sponsored protection. The examine discovered that 23 % of adults aged 19–64 had been insured all yr however underinsured, and 11 % had been uninsured.
“Employers ought to do analytics to find out what a change in plan design will imply for lower-wage staff – and what number of can be prone to face monetary insecurity resulting from medical prices,” he stated.
For advantages advisors working the 2027 renewal, meaning reframing cost-shifting conversations with employer shoppers as a workforce and retention threat evaluation, not merely a budgeting train. Brokers trying to perceive how employer cost-sharing selections are reshaping group well being plan design can draw on a rising physique of IBB evaluation protecting profit plan tendencies and renewal techniques.
The seller measurement hole
The survey additionally reveals a troubling disconnect in how employers consider the purpose options they deploy. The common employer now works with 13 well being and wellbeing distributors – down from a peak of 14 in 2025, suggesting early indicators of consolidation, however nonetheless effectively above the 11 distributors recorded in 2022.
Regardless of that progress, solely 34 % consider the medical affect of their applications and solely 42 % the monetary affect, per WTW’s information. In different phrases, most employers can’t totally reply whether or not the distributors they’re paying for are working.
Levin-Scherz, who brings each a doctor’s perspective and advantages technique experience to the query, was direct. “Clearly, employers ought to do rigorous measurement to make certain that their vendor applications are delivering worth,” he stated. “Many vendor ROI analytics are deeply flawed, so employers ought to search an outdoor get together to assessment program effectiveness.”
The identical scrutiny is extending to pharmacy profit managers (PBMs). Employer satisfaction with PBMs has deteriorated sharply: the Internet Promoter Rating for PBMs fell from −10 in 2024 to −25 in 2026, with confidence {that a} PBM secures probably the most advantageous pricing dropping 15 share factors, from 54 % to 39 %.
Consequently, 64 % of employers are already taking or planning concrete motion on their PBM relationships – together with taking contracts out to bid and assessing unbiased PBMs. Brokers advising mid-market shoppers on vendor consolidation and pharmacy profit supervisor contract assessment methods are more and more positioned because the analytical layer employers lack internally.
GLP-1s and specialty medication: the pharmacy stress level
Pharmacy advantages – notably specialty medication and glucagon-like peptide-1 (GLP-1) drugs – now characterize roughly one-quarter of whole employer healthcare spending, and when medication administered by way of medical advantages are included, WTW estimates pharmaceutical spending reaches roughly 36 % of whole healthcare claims. The determine has made pharmacy profit administration a frontline challenge in each renewal dialog.
GLP-1 protection is changing into one of the vital consequential selections employers face heading into 2027. For the primary time in three years, the share of employers protecting GLP-1s for weight reduction has declined, dropping from 56 % to 53 %.
The pattern beneath that headline is extra telling: employers with protection in place and planning to maintain it fell from 48 % to 37 % yr over yr, whereas these contemplating elimination almost doubled, from 9 % to 16 %. Amongst employers pulling again, value is the overwhelming driver, cited by 91 %.
Levin-Scherz outlined a number of levers out there to employers and their advisors. On GLP-1s: “Costs direct to customers are decrease, so employers can preserve protection by subsidizing direct buy. That is arduous for lower-wage employees although, and these bills usually are not utilized to deductible or out-of-pocket most.”
He famous that employers typically add program participation necessities to focus protection on probably the most dedicated customers – and WTW’s information exhibits this method produces higher medical outcomes, with staff going through restrictions almost twice as prone to scale back their physique mass index by 10 or extra factors in contrast with these with out them.
For different specialty medication – which already drive roughly half of whole pharmacy value – he pointed to biosimilars as a big financial savings alternative.
PBMs “typically want their very own biosimilar medication which value way more than different medication,” he stated, including that altering the positioning of service to keep away from massive outpatient hospital charges and drug markups also can yield significant financial savings. WTW’s survey initiatives that employer efforts to affect specialty pharmacy website of care will soar from 25 % immediately to 57 % by 2028 as a rising set of vendor choices makes motion extra possible.
Brokers advising plan sponsors on specialty pharmacy value administration and site-of-care methods for group well being plans ought to word: the lever most underused might merely be unbiased scrutiny of what the PBM is definitely recommending.
Legislative reduction: doable however not imminent
Including to the voices considering the affect of the November 2026 midterm election outcomes, Levin-Sherz doesn’t see a magic repair for top well being plan prices.
“Nobody ought to count on that the midterm election outcomes will result in fast reduction from excessive charges of medical inflation,” he stated. He famous that expiring subsidies for Inexpensive Care Act (ACA) market plans and coming Medicaid cuts might truly push prices increased for employer-sponsored plans by lowering the monetary stability of safety-net hospitals.
Some reduction might come from state motion. Indiana and Delaware have handed laws that will restrict hospital payments to a a number of of the Medicare price schedule – a mannequin that might produce significant financial savings for employer-sponsored plans if adopted extra broadly. On the federal degree, he sees potential for bipartisan laws to control PBMs and carriers, and to handle excessive arbitration awards beneath the No Surprises Act.
The Facilities for Medicare & Medicaid Companies (CMS) has revealed detailed No Surprises Act steerage for employer group well being plans that brokers and plan sponsors ought to assessment forward of 2027 renewals.
“These adjustments will not resolve our medical value disaster,” Levin-Scherz stated, “however they’ll assist.”

